Prophylactic antivirals prevent CMV disease in transplant recipients

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1492, 2005-01, pp. : 15-15

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Preemptive vs prophylactic therapy for CMV disease prevention

Inpharma, Vol. 1, Iss. 1630-1631, 2008-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

Valganciclovir for the prevention and treatment of CMV in solid organ transplant recipients

By Åsberg Anders Rollag Halvor Hartmann Anders

Expert Opinion on Pharmacotherapy, Vol. 11, Iss. 7, 2010-05 ,pp. : 1159-1166

Informa Healthcare

Access to resources Recommend Favorite

Strategies to Prevent Cellular Rejection in Pediatric Heart Transplant Recipients

By Denfield Susan W.

Pediatric Drugs, Vol. 12, Iss. 6, 2010-12 ,pp. : 391-403

Adis International

Access to resources Recommend Favorite

Pre-emptive ganciclovir preferred for CMV disease after kidney transplant

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 273, 2000-01 ,pp. : 7-7

Adis International

Access to resources Recommend Favorite

A 24-week course of ganciclovir prophylaxis lowers the risk of cytomegalovirus (CMV) infection in renal transplant recipients

Inpharma, Vol. 1, Iss. 1541, 2006-01 ,pp. : 12-12

Adis International

Access to resources Recommend Favorite